Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months

BACKGROUND: Fingolimod, an oral sphingosine 1-phosphate receptor immunomodulator, is approved in Europe for people with multiple sclerosis (pwMS) with highly active disease despite a full and adequate course of treatment with ≥ 1 disease-modifying therapy or patients with rapidly evolving severe rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Tichá, Veronika, Počíková, Zuzana, Vytlačil, Josef, Štěpánová, Radka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011961/
https://www.ncbi.nlm.nih.gov/pubmed/35428205
http://dx.doi.org/10.1186/s12883-022-02656-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011961/
https://www.ncbi.nlm.nih.gov/pubmed/35428205
http://dx.doi.org/10.1186/s12883-022-02656-8

Ejemplares similares